Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA

Aptose Biosciences Inc.

2026-Q1 EPS reported -$2.99

Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.
Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).
TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.
Luxeptinib license rights returned to CGI; program winding down.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aptose Biosciences Inc. reported the first quarter ended March 31, 2026 results: net income $7.6 million, EPS $(2.99) per common share, basic and diluted.

Period: the first quarter ended March 31, 2026
Net income: $7.6 million
EPS: $(2.99) per common share, basic and diluted
Result: reported results

Exact text from the filing

Net loss per common share, basic and diluted $ (2.99 )

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-003381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.